Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Zander

Showing results (141-150 of 206) with videos related to

Pageof 21
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 27, 2010
Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitorsSascha Ansén, Christopher Bangard, Silvia Querings, et al.
BMC Gastroenterology|February 6, 2019
Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinomaAlexander Quaas, Carina Heydt, Dirk Waldschmidt, et al.
Journal of Translational Medicine|August 17, 2023
The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosisAdrian Georg Simon, Su Ir Lyu, Mark Laible, et al.
Investigational New Drugs|November 11, 2019
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancerJohanna C Bendell, Helge G Bischoff, Jimmy Hwang, et al.
Cancer Immunology, Immunotherapy : CII|January 22, 2020
Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinomaSvenja Wagener-Ryczek, Max Schoemmel, Max Kraemer, et al.
Journal of Cancer Research and Clinical Oncology|March 31, 2023
Two decades of gastric and gastroesophageal junction cancer surgeryPatrick S Plum, Aylin Pamuk, Atakan G Barutcu, et al.
The Oncologist|August 19, 2023
Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal CancerEric Van Cutsem, Rona Yaeger, Jean-Pierre Delord, et al.
Cancers|February 21, 2020
Dickkopf-2 (DKK2) as Context Dependent Factor in Patients with Esophageal AdenocarcinomaLars M Schiffmann, Heike Loeser, Anne Sophie Jacob, et al.
BMC Cancer|June 2, 2019
Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinomaLars M Schiffmann, Heike Göbel, Heike Löser, et al.
Plos One|January 12, 2013
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinibMatthias Scheffler, Thomas Zander, Lucia Nogova, et al.
Pageof 21

Showing results (141-150 of 206) with videos related to

Sort By:
Pageof 21
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 27, 2010
Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitorsSascha Ansén, Christopher Bangard, Silvia Querings, et al.
BMC Gastroenterology|February 6, 2019
Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinomaAlexander Quaas, Carina Heydt, Dirk Waldschmidt, et al.
Journal of Translational Medicine|August 17, 2023
The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosisAdrian Georg Simon, Su Ir Lyu, Mark Laible, et al.
Investigational New Drugs|November 11, 2019
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancerJohanna C Bendell, Helge G Bischoff, Jimmy Hwang, et al.
Cancer Immunology, Immunotherapy : CII|January 22, 2020
Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinomaSvenja Wagener-Ryczek, Max Schoemmel, Max Kraemer, et al.
Journal of Cancer Research and Clinical Oncology|March 31, 2023
Two decades of gastric and gastroesophageal junction cancer surgeryPatrick S Plum, Aylin Pamuk, Atakan G Barutcu, et al.
The Oncologist|August 19, 2023
Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal CancerEric Van Cutsem, Rona Yaeger, Jean-Pierre Delord, et al.
Cancers|February 21, 2020
Dickkopf-2 (DKK2) as Context Dependent Factor in Patients with Esophageal AdenocarcinomaLars M Schiffmann, Heike Loeser, Anne Sophie Jacob, et al.
BMC Cancer|June 2, 2019
Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinomaLars M Schiffmann, Heike Göbel, Heike Löser, et al.
Plos One|January 12, 2013
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinibMatthias Scheffler, Thomas Zander, Lucia Nogova, et al.
Pageof 21